Skip to main content

CRYSVITA is the first and only FDA-approved treatment for TIO

CRYSVITA is an approved treatment for FGF23-related hypophosphatemia in TIO in adults and children 2 years of age or older when the tumor cannot be located or removed
CRYSVITA works to raise the amount of phosphorus in the body by decreasing FGF23 activity

The underlying cause of hypophosphatemia in TIO is too much FGF23

Tumor and fibroblast growth factor 23 (FGF23)

1.

Tumors in the body produce too much of a hormone called fibroblast growth factor 23 (FGF23)

Kidney releasing too much phosphorus in urine

2.

Extra FGF23 leads to the body releasing too much phosphorus through the urine

Weakened bone from lack of phosphorus

3.

Low phosphorus levels can lead to weakened bones and the symptoms of TIO

CRYSVITA blocks FGF23

CRYSVITA blocking FGF23

1.

CRYSVITA blocks FGF23

CRYSVITA restoring phosphorus absorption in the kidneys

2.

This helps restore phosphorus reabsorption in the kidneys

Phosphorus being deposited in the bones

3.

Phosphorus can then be deposited into the bones

What are the possible side effects of CRYSVITA?

Adverse reactions that were seen in adults with TIO:

Tooth abscess
Muscle spasms
Dizziness
Constipation

Injection site reaction
Rash
Headache

Ready to experience CRYSVITA?

Getting started on CRYSVITA can help you begin to manage this condition.

Find out how CRYSVITA can help manage your TIO

See CRYSVITA results

Discover how CRYSVITA helped people with TIO

Getting started with CRYSVITA

What you need to know before starting CRYSVITA treatment

See safety information for CRYSVITA

Learn about the safety profile of CRYSVITA

Stay informed

Learn more about CRYSVITA, connect with a support community, and receive invites to important educational events.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 2 years of age and older with fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumor-induced osteomalacia (TIO) when the tumor cannot be located or removed.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 2 years of age and older with fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumor-induced osteomalacia (TIO) when the tumor cannot be located or removed.

Important Safety Information

You should not take CRYSVITA if:

You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).

Your phosphorus levels from a blood sample are within or above the normal range for age.
You have kidney problems.

What is the most important information you should know about CRYSVITA?

Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA.
High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels.
Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma).
If you are taking CRYSVITA for TIO, your doctor will have you stop your CRYSVITA treatment temporarily if you are undergoing treatment for your tumor (e.g., surgical removal of the tumor or radiation therapy).

What are the possible side effects of CRYSVITA?

Adverse reactions that were seen in adults with TIO are:
- Tooth abscess
- Muscle spasms
- Dizziness
- Constipation
- Injection site reaction
- Rash
- Headache

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

An allergic reaction such as rash or hives
A rash, swelling, bruising, or other reaction at the injection site
New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 2 years of age and older with fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumor-induced osteomalacia (TIO) when the tumor cannot be located or removed.

Important Safety Information

You should not take CRYSVITA if:

You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
Your phosphorus levels from a blood sample are within or above the normal range for age.
You have kidney problems.

What is the most important information you should know about CRYSVITA?

Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA.
High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels.
Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma).
If you are taking CRYSVITA for TIO, your doctor will have you stop your CRYSVITA treatment temporarily if you are undergoing treatment for your tumor (e.g., surgical removal of the tumor or radiation therapy).

What are the possible side effects of CRYSVITA?

Adverse reactions that were seen in adults with TIO are:
- Tooth abscess
- Muscle spasms
- Dizziness
- Constipation
- Injection site reaction
- Rash
- Headache

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

An allergic reaction such as rash or hives
A rash, swelling, bruising, or other reaction at the injection site
New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information.